CLINDACYL 25 MG TABLETS FOR DOGS AND CATS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
30-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CLINDAMYCIN
Available from:
Vetoquinol UK Limited
ATC code:
QJ01FF01
INN (International Name):
CLINDAMYCIN
Dosage:
25 Milligram
Pharmaceutical form:
Tablets
Prescription type:
POM
Therapeutic group:
Canine, Feline
Therapeutic area:
Clindamycin
Therapeutic indications:
Antibacterial
Authorization status:
Authorised
Authorization date:
2000-09-01
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clindacyl 25 mg Tablets for dogs and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE
Clindamycin
25 mg
(as Clindamycin Hydrochloride)
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
A small white tablet, with a break line on one side and the letter J embossed on both sides of the break line.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clindacyl 25 mg Tablets are antibiotics indicated for the treatment of infected wounds, abscesses, pyoderma and oral
cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, pneumococci,
bacteroidaceae, _Fusobacterium necrophorum, Clostridium perfringens _and osteomyelitis caused by _Staphylococcus_
_aureus_. Clindacyl 25 mg Tablets can also be used to help provide antimicrobial cover during dental procedures.
4.3 CONTRAINDICATIONS
Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 20/05/2011_
_CRN 7007910_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged osteomyelitis therapy of one month or greater, periodic liver and kidney function tests and blood
counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe
metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose
clindamycin therapy. The product should not be used in
Read the complete document
